Changes in biomarkers of lipid in juvenile idiopathic arthritis and its association with various disease parameters: a 6-month follow-up study
DOI:
https://doi.org/10.18203/2349-3291.ijcp20241357Keywords:
Lipid profile, Juvenile idiopathic arthritis, Juvenile disease activity score 27Abstract
Background: The objectives of our study were to determine the changes in lipid profile (total cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C)) in juvenile idiopathic arthritis (JIA) and assess its association with epidemiological and clinical profile of JIA patients.
Methods: This observational study was performed with 46 patients at presentation followed by 38 cases at 3 months and 18 cases at 6 months of follow up. Their demographic profile and clinical parameters including juvenile disease activity score (JADAS 27) were compared with the biomarkers of lipid profile.
Results: The mean (SD) age was 105.85 (20.23) months at first visit with mean (SD) disease duration being 15 (6.4) months. Twenty-six participants had oligoarthritic (56.5%), while the rest had polyarthritis (43.4%). Most of the patients had borderline raised TG and LDL-C (cases with raised TG n=14 (30.4%), 12 (31.5%), 5 (27.7%) at 1st visit, 3 months, and 6 months respectively and LDL-C n=12 (26%), 10 (26.3%), 6 (33.3%) at 1stvisit, 3 months, and 6 months respectively). HDL-C level was low in 36 (78.2%) cases at first visit, 28 cases (73.6%) at 3 months and 12 cases (66.6%) at 6 months respectively. Lipid profile was significantly affected by gender difference, duration of disease and drug therapy (p<0.05). Significant association have been found between JADAS score and TGL level with p value 0.03.
Conclusions: Children with JIA definitely suffer from dyslipidemia. Among the biomarkers of lipid profile, low level of HDL-C is one of the most important highlights of our study. Further studies can help to strengthen the findings and formulate necessary interventions at an early stage.
References
Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton. J Rheumatol. 2001;31:390-2.
Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet. 2011;377(9783):2138-49.
Huang JL. New advances in juvenile idiopathic arthritis. Chang Gung Med J. 2012;35(1):1-14.
Woo P. Cytokines in juvenile chronic arthritis. Baillieres Clin Rheumatol. 1998;12(2):219-28.
Savel J, Lafitte M, Pucheu Y, Pradeau V, Tabarin A, Couffinhal T. Very low levels of HDL cholesterol and atherosclerosis, a variable relationship--a review of LCAT deficiency. Vasc Health Risk Manag. 2012;8:357-61.
Sun DM, Ding Y, Zhnag Y, Xia K. Serum lipid profile in children with different subtypes of juvenile idiopathic arthritis. Zhongguo Dang Dai Er Ke Za Zhi. 2019;21(6):547-51.
Skare TL, Silva MB, Negreiros P. Lipid profile in adult patients with idiopathic juvenile arthritis. Rev Bras Reumatol. 2013;53(4):371-4.
Consolaro A, Giancane G, Schiappapietra B, Davì S, Calandra S, Lanni S, et al. Clinical outcome measures in juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2016;14(1):23.
Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011;128(5):S213-56.
Kavey RE, Allada V, Daniels SR, Hayman LL, McCrindle BW, Newburger JW, et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation. 2006;114(24):2710-38.
Bakkaloglu A, Kirel B, Ozen S, Saatçi U, Topaloğlu, Beşbaş N. Plasma lipids and lipoproteins in juvenile chronic arthritis. Clin Rheumatol. 1996;15(4):341-5.
Marangoni RG, Hayata AL, Borba EF, Azevedo PM, Bonfá E, Schainberg CG. Decreased high-density lipoprotein cholesterol levels in polyarticular juvenile idiopathic arthritis. Clinics (Sao Paulo). 2011;66(9):1549-52.
Guha S, Haldar A, Choubey A, Pal SR. Premature atherosclerosis in Indian children with Juvenile Idiopathic Arthritis: A cross-sectional study. Sri Lanka J Child Health. 2021;50(1):32-7.
Bohr AH, Pedersen FK, Nielsen CH, Müller KG. Lipoprotein cholesterol fractions are related to markers of inflammation in children and adolescents with juvenile idiopathic arthritis: a cross sectional study. Pediatric Rheumatology Online J. 2016;14(1):61.
Rodrigues WDR, Sarni ROS, Fonseca FLA, Araújo A, Len CA, Terreri MT. Biomarkers of lipid metabolism in patients with juvenile idiopathic arthritis: relationship with disease subtype and inflammatory activity. Pediatric Rheumatology Online J. 2021;19(1):66.
Nasef SI, Abouzied SSIM, Elfiky SM, Zeiton A. Lipid profile disorders in children and adolescents with Juvenile Idiopathic Arthritis. Br J Rheumatol. 2021;60(5).
Urban M, Pietrewicz E, Górska A, Głowińska B. Lipids and homocysteine level in juvenile idiopathic arthritis. Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego. 2004;17(99):235-8.
Assmann G, Gotto AM Jr. HDL cholesterol and protective factors in atherosclerosis. Circulation. 2004 Jun 15;109(23):III8-14.
Tselepis AD, Elisaf M, Besis S, Karabina SA, Chapman MJ, Siamopoulou A. Association of the inflammatory state in active juvenile rheumatoid arthritis with hypo-high-density lipoproteinemia and reduced lipoprotein-associated platelet-activating factor acetylhydrolase activity. Arthritis Rheum. 1999;42(2):373-83.
Navarro-Millan I, Charles-Schoeman C, Yang S, Bathon JM, Bridges SL, Jr, Chen L, et al. Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial. Arthritis Rheum. 2013;65(6):1430-8.
